NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-031-2020-0-CU-22 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION CU National Stage 2022-0044 Pending
NCI E-061-2021-0-US-01 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES USING HIGH-THROUGHPUT SINGLE-CELL SEQUENCING US 63/148,774 Abandoned
NCI E-031-2020-0-IN-08 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION IN National Stage 202247050250 Pending
NIDA E-053-2016-2-AU-03 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF AU National Stage 2019340675 Pending
NCCIH E-081-2020-0-AU-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN AU National Stage 2021220883 Pending
NCI E-031-2020-0-AU-04 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION AU National Stage 2021221138 Pending
NCI E-031-2020-0-BR-14 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION BR National Stage BR112022015888-2 Pending
NIAID E-086-2020-0-PCT-02 SARS-CoV-2 VACCINE PCT PCT PCT/US2021/017709 Expired
NIAID E-086-2020-0-CN-07 SARS-CoV-2 VACCINE CN National Stage 202180027866.X Pending
NIAID E-086-2020-0-EP-08 SARS-COV-2 VACCINE EP National Stage 21710716.8 Pending
NIAID E-086-2020-0-ID-10 SARS-CoV-2 VACCINE ID National Stage P00202209715 Pending
NIAID E-086-2020-0-JP-12 SARS-CoV-2 VACCINE JP National Stage 2022-548435 Pending
NIAID E-086-2020-0-MX-14 SARS-CoV-2 VACCINE MX National Stage MX/a/2022/009836 Pending
NIAID E-086-2020-0-CA-06 SARS-CoV-2 VACCINE CA National Stage 3170322 Pending
NIAID E-086-2020-0-BR-05 SARS-CoV-2 VACCINE BR National Stage BR112022015628-6 Pending
NIAID E-086-2020-0-AU-04 SARS-CoV-2 VACCINE AU National Stage 2021221127 Pending
NIAID E-086-2020-0-ZA-15 SARS-CoV-2 VACCINE ZA National Stage 2022/08951 Pending
NIAID E-086-2020-0-KR-13 SARS-CoV-2 VACCINE KR National Stage 10-2022-7031250 Pending
NIAID E-086-2020-0-TH-16 SARS-CoV-2 VACCINE TH National Stage 2201005020 Pending
NIAID E-086-2020-0-IL-11 SARS-CoV-2 VACCINE IL National Stage 295301 Pending
NIAID E-086-2020-0-VN-17 SARS-CoV-2 VACCINE VN National Stage 1-2022-05526 Pending
NCI E-265-2015-0-AU-18 T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS` AU DIV 2021200833 Issued
NCI E-234-2014-1-KR-02 B T METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF KR DIV 10-2021-7004191 Abandoned
NIAID E-099-2016-1-NZ-20 USE OF GRAM NEGATIVE SPECIES TO TREAT ATOPIC DERMATITIS NZ National Stage 772826 Abandoned
NHGRI E-034-2019-0-US-07 Targeted Integration Into The Albumin (Alb) Locus As A Treatment For Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MUT) Deficiency US National Stage 17/267,482 Pending
NIAID E-191-2023-0-US-01 FORMULATION, STABILITY, PHARMACOKINETIC, AND MODELING STUDIES FOR TESTS OF SYNERGISTIC COMBINATIONS OF ORALLY AVAILABLE APPROVED DRUGS AGAINST EBOLA VIRUS IN VIVO US 63/147,587 Expired
NIAID E-037-2021-0-US-01 Antibodies Targeting The Spike Protein Of Coronaviruses US 63/147,419 Abandoned
NCI E-085-2013-0-HK-28 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood HK CN 42021025138.5 Issued
NCI E-198-2018-0-US-07 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF US National Stage 17/266,419 12012463 Issued PDF
NCATS E-176-2018-0-PCT-02 TAT PEPTIDE BINDING PROTEINS AND USES THEREOF PCT PCT PCT/US2021/016959 Expired
NIAID E-168-2020-2-PC-01 Corona Virus Binders PCT PCT PCT/EP2021/052885 Expired
NIAID E-168-2020-2-US-01 Corona Virus Binders US National Stage 17/760,300 Pending
NIAID E-168-2020-2-CN-01 Corona Virus Binders CN National Stage 2021800270795 Pending
NCATS E-176-2018-0-EP-04 TAT PEPTIDE BINDING PROTEINS AND USES THEREOF EP National Stage 21709825.0 Pending
NIAID E-168-2020-2-EP-01 Corona Virus Binders EP National Stage 21712040.1 Pending
NIAID E-168-2020-2-JP-01 Corona Virus Binders JP National Stage 2022-548140 Pending
NIAID E-168-2020-2-IL-01 Corona Virus Binders IL National Stage 295389 Pending
NIAID E-168-2020-2-HK-01 Corona Virus Binders HK EP 62023071524.0 Pending
NCATS E-176-2018-0-IN-03 TAT PEPTIDE BINDING PROTEINS AND USES THEREOF IN National Stage 202217049798 Pending
NIAID E-168-2020-2-AU-01 Corona Virus Binders AU National Stage 2021217563 Pending
NCATS E-176-2018-0-CA-06 TAT PEPTIDE BINDING PROTEINS AND USES THEREOF CA National Stage 3167027 Pending
NCI E-064-2021-0-US-01 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoC-2 Transmission And Infection US 63/146,279 Abandoned
NCATS E-176-2018-0-KR-05 TAT PEPTIDE BINDING PROTEINS AND USES THEREOF KR National Stage 10-2022-7030361 Pending
NIAID E-168-2020-2-KR-01 Corona Virus Binders KR National Stage 10-2022-7030791 Pending
NIAID E-052-2017-4-JP-51 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection JP DIV 2021-016190 Issued
NIDCR E-186-2009-0-US-09 APOPTOTIC CELL-MEDIATED INDUCTION OF ANTIGEN SPECIFIC REGULATORY T-CELLS FOR THE THERAPY OF AUTOIMMUNE DISEASES IN ANIMALS AND HUMANS US CON 17/167,737 Pending
NIDA E-053-2016-2-US-06 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF US National Stage 17/265,150 11337971 Issued PDF
NIAMS E-216-2010-0-US-09 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING LUPUS US CON 17/162,982 Abandoned
NCI E-243-2020-0-US-01 NEAR INFRARED PHOTOIMMUNOTHERAPY (NIR-PIT) COMBINATION THERAPY TO TREAT CANCER US 63/143,068 Abandoned
NHLBI E-056-2021-0-US-01 A New Molecular Scaffold For Targeting HRpn13 US 63/143,398 Abandoned